NRSN NeuroSense Therapeutics Ltd: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

NeuroSense Therapeutics (NRSN) is accelerating the development of its breakthrough PrimeC combination therapy to combat ALS. The monopoly status of these future drugs will grant the company full pricing power. The biopharmaceutical ecosystem is creating a closed treatment loop with high switching costs, as confirmed by the trailing twelve-month (TTM) EPS growth chart on GURU.Markets, where the current metric is 31.20.

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over the trailing twelve months, reflecting the dynamics of real shareholder income relative to the previous year. For NeuroSense Therapeutics (NRSN), the current EPS YoY TTM growth trend serves as an indicator of financial efficiency amid the clinical trials of the PrimeC drug and the company's acquisition prospects.